Evidence map›Paper›PMID 36617559›Full record

ReviewEuropean journal of medical research2023

How to diagnose iron deficiency in chronic disease: A review of current methods and potential marker for the outcome.

Martina Rohr, Vincent Brandenburg, Hans-Peter Brunner-La Rocca

Open access · goldAbstract readReview
In one paragraph

Review in European journal of medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
18.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Diagnosis and management of iron deficiency in females.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Review
  14. Article
  15. Article
  16. Review
  17. International journal of molecular sciences · 2025
    Article
  18. Article
  19. Article
  20. Iron Deficiency and All-Cause Hospitalization Risk in a Clinical Cohort of COPD.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Martina RohrVifor Pharma Deutschland GmbH, Baierbrunner Straße 29, 81379, Munich, Germany. ma-rohr@web.de.ORCID http://orcid.org/0000-0002-4729-8495
Vincent BrandenburgDept of Cardiology and Nephrology, Rhein-Maas Klinikum Würselen, Mauerfeldchen 25, 52146, Würselen, Germany.
Hans-Peter Brunner-La RoccaCardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands.
Klinikum Rheine · DEMaastricht University Medical Centre · NLVifor Pharma (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Iron deficiency (ID) is the most common nutritional disorder worldwide. It is often observed in patients with chronic diseases, such as heart failure (HF), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and cancer. ID is associated with poor clinical outcome, including poor performance, reduced quality of life, as well as increased hospitalization and mortality. The aim of this review is to provide an overview about the role of ID in chronic diseases (HF, CKD, IBD, cancer) regarding their current definitions and clinical relevance; diagnostic accuracy of iron parameters in chronic inflammatory conditions and its potential as prognostic markers. Due to different definitions and guideline recommendations of ID, various laboratory parameters for ID diagnostic exist and there is no general consensus about the definition of ID and its treatment. Still, a general trend can be observed across all investigated indications of this review (HF, CKD, IBD, cancer) that serum ferritin and transferrin saturation (TSAT) are the two parameters mentioned most often and emphasized in all guidelines to define ID and guide treatment. The most commonly used threshold values for the diagnosis of ID are TSAT of < 20% and serum ferritin of < 100-300 µg/L. Noteworthy, both TSAT and particularly ferritin are frequently applied, but both may vary due to inflammatory conditions. Studies showed that TSAT is less affected by inflammatory processes and may therefore be more accurate and reliable than serum ferritin, particularly in conditions with elevated inflammatory state. A low iron status and particularly a low TSAT value was associated with a poor outcome in all investigated indications, with the strongest evidence in HF patients. Routine surveillance of iron status in these groups of patients with chronic conditions is advisable to detect ID early. Depending on the inflammatory state, TSAT < 20% may be the more accurate diagnostic marker of ID than ferritin. Moreover, TSAT may also be the more reliable estimate for the prognosis, particularly in HF.

Indexed as

Heart FailureInflammatory Bowel DiseasesIron DeficienciesRenal Insufficiency, ChronicBiomarkersChronic DiseaseFerritinsHumansIronQuality of LifeTransferrinBiomarkersFerritinsIronTransferrin

Identifiers

PMID36617559
PMCPMC9827648
OpenAlexW4313813091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.